PRAX News and Press, Praxis Precision Medicines Inc. From 11/09/22

Praxis Precision Medicines press release ( NASDAQ: PRAX ): Q3 GAAP EPS of -$0.96 misses by $0.04 . $123.7 million in cash, cash equivalents and marketable securities, compared to $275.9 million in cash. The Company’s cash, cash equivalents and marketable sec...

PRAX-944 Phase 2b Essential1 study topline results for essential tremor expected in 1Q23 PRAX-222 EMBRAVE study for SCN2A-DEE to initiate in 4Q22; topline results for initial dose cohort expected in 2023 PRAX-628 Phase 1 healthy volunteer study to initiate in 4Q22; f...

BOSTON, Sept. 21, 2022 (GLOBE NEWSWIRE) -- Praxis Precision Medicines , Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibiti...

Invitae's Real-World Ciitizen Data Utilized in Praxis Precision Medicines' PRAX-222 IND Filing PR Newswire – First use of Ciitizen platform as source of real-world data in regulatory filing – SAN FRANCISCO and BOSTON , Sept. 20, 2022 ...

BOSTON, Sept. 07, 2022 (GLOBE NEWSWIRE) -- Praxis Precision Medicines , Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibiti...

BOSTON, Sept. 07, 2022 (GLOBE NEWSWIRE) -- Praxis Precision Medicines , Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibiti...

Praxis Precision Medicines press release ( NASDAQ: PRAX ): Q2 GAAP EPS of -$1.32 misses by $0.02 . Cash, cash equivalents and marketable securities $165.4M For further details see: Praxis Precision Medicines GAAP EPS of -$1.32 misses by $0.02

PRAX-944 Phase 2b Essential1 Study topline results expected in 4Q22; primary endpoint updated to efficacy PRAX-562 Phase 1 study completed, confirming biomarker change and potential for wide therapeutic window Cash and investments of $165.4 million as of June 30, 20...

BOSTON, Aug. 03, 2022 (GLOBE NEWSWIRE) -- Praxis Precision Medicines , Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibitio...

Gainers: Tactile Systems Technology (TCMD) +4.9%. Roth CH Acquisition (ROCC) +4.9%. Hertz Global Holdings (HTZ) +4.8%. WM Technology (MAPS) +4.7%. LendingTree (TREE) +4%. Losers: Icosavax (ICVX) -22.0%. AeroVironment (AVAV) -10.1%. Playa Hotels & Resorts (PLYA) -3.0%. 89bio (ETN...